HUM Humana (HUM) Insider Trading, Ownership & Congress Trades
Insurance · Hospital & medical service plans · CIK 0000049071
Congress · 1
Insider buyers, 180 days
0
Funds added, last quarter
565
13F, latest reported quarter
What the filings say about HUM
Congress, 1 year
1 bought · 3 sold
Latest: sale, 2026-02-10
Humana insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for HUMANA INC in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 6.9% of the 11,657 shares held after it.
- No other insider bought within 30 days.
- 565 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President, CenterWell Shetty Sanjay K bought about $150.0K of HUM on Feb 23, 2026; 565 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 21.4% of the 30,474 shares held after it.
- No other insider bought within 30 days.
- 565 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President & CEO Rechtin James A. bought about $1.5M of HUM on May 14, 2025, the largest insider purchase at the company on our record; 565 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Feb 27, 2023.
- The trade is 45.3% of the 8,181 shares held after it.
- No other insider sold within 30 days.
- 565 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Administrative Officer Huval Timothy S. sold about $948.9K of HUM on Dec 31, 2024, the largest insider sale at the company since 2023; 565 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 21.1% of the 2,578 shares held after it.
- No other insider bought within 30 days.
- 565 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Mesquita Jorge S. bought about $200.1K of HUM on Feb 20, 2024, the largest insider purchase at the company on our record; 565 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Nov 3, 2022.
- The trade is 48.9% of the 5,431 shares held after it.
- No other insider sold within 30 days.
- 565 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Diamond Susan M sold about $1.4M of HUM on May 4, 2023; 565 funds added in the latest 13F quarter.29 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
1 member bought in the last year
the lowest in Insurance
Funds
565 funds bought in last quarter
more than 87% of Insurance
Revenue
+31.6% year over year
more than 81% of Insurance
Margin
20.4% net margin
more than 71% of Insurance
Buybacks
$107.0M repurchased, FY to 2026-03-31
below 61% of Insurance
Short interest
3.1% of the float short (float per yahoo 2026-10-27) · 2.0 days to cover · settled 2026-10-15
more than 56% of Insurance
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch HUM
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+44.8%12M
Insider buy
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns HUM: institutional holders (13F)
13F holdings, latest reported quarter
10,940,380 sh
$4.3B
10,417,803 sh
$4.1B
7,843,620 sh
$3.1B
5,818,956 sh
$2.3B
5,457,072 sh
$2.2B
Congress trades in HUM
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Sold 2026-02-10 · disclosed 30 days later
$1,001 - $15,000
Sold 2025-11-12 · disclosed 33 days later
$1,001 - $15,000
Sold 2025-10-31 · disclosed 21 days later
$1,001 - $15,000
Sold 2025-10-30 · disclosed 22 days later
$1,001 - $15,000
Bought 2025-10-30 · disclosed 22 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
HUM planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
HUM mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Pzena Mid Cap Value Fund
$6.9M position · as of 2026-05-31
6.7%
Pzena U.S. Large Cap Value ETF
$3.6M position · as of 2026-05-31
5.9%
Classic Value Fund
$27.9M position · as of 2026-07-31
5.1%
American Customer Satisfaction ETF
$5.5M position · as of 2026-06-30
4.9%
DIAMOND HILL MID CAP FUND
$3.5M position · as of 2026-06-30
4.7%
iShares U.S. Healthcare Providers ETF
$55.2M position · as of 2026-06-30
4.7%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Government contracts
Award ceilings over the contract's life, subsidiaries included.
Not annual revenue (USASpending.gov).
Department Of Defense
TRICARE MANAGED CARE SUPPORT SERVICES CONTRACT, 5TH GENERATION EAST REGION · 2023-02-01
$9.3B
Federal awards ≥ $25M in the last 90 days, matched via the SAM.gov parent registry
Corporate PAC
The company's PAC: committee totals only, never individual donors (FEC).
Humana Inc. Political Action Committee
Cycle 2026 · $1,203K spent
$1.1M
Federal Election Commission, matched by the PAC's connected organisation
Executive pay vs shareholder return · Mr Broussard
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2023
$16.3M
-$37.7K
$3.9M
+28%
+36%
2022
$17.2M
$30.4M
$4.2M
+43%
+37%
2021
$16.5M
$25.8M
$4.1M
+28%
+47%
2020
$16.5M
$28.4M
$4.1M
+13%
+18%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 565 funds added last quarter, 1 House member(s) bought in 12 months, disclosed weeks after the trade. Each figure is a federal filing, dated the day it went public.
HUM financials
Revenue growth
+31.6%
XBRL, annual
Net margin
20.4%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$137.2B
four quarters, 2025-04-01 to 2026-03-31
Revenue, TTM HUM
| FY Dec 2025 | $129.7B |
| FY Dec 2024 | $117.8B |
| FY Dec 2023 | $106.4B |
| FY Dec 2022 | $92.9B |
| FY Dec 2021 | $83.1B |
| Mar 2026 | $39.6B |
| Dec 2025 | $32.5B |
| Sep 2025 | $32.6B |
| Jun 2025 | $32.4B |
| Mar 2025 | $32.1B |
| Dec 2024 | $29.2B |
| Sep 2024 | $29.4B |
| Jun 2024 | $29.5B |
At each fiscal year end
Single quarter
Net margin, TTM
+0.8%
net income over revenue, 2025-04-01 to 2026-03-31
Net margin, TTM HUM
| FY Dec 2025 | +0.9% |
| FY Dec 2024 | +1.0% |
| FY Dec 2023 | +2.3% |
| FY Dec 2022 | +3.0% |
| FY Dec 2021 | +3.5% |
| Mar 2026 | +3.0% |
| Dec 2025 | -2.4% |
| Sep 2025 | +0.6% |
| Jun 2025 | +1.7% |
| Mar 2025 | +3.9% |
| Dec 2024 | -2.4% |
| Sep 2024 | +1.6% |
| Jun 2024 | +2.3% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$1.3B
operating cash flow minus capex, 2025-04-01 to 2026-03-31
Free cash flow, TTM HUM
| FY Dec 2025 | $375.0M |
| FY Dec 2024 | $2.4B |
| FY Dec 2023 | $3.0B |
| FY Dec 2022 | $3.5B |
| FY Dec 2021 | $920.0M |
| Mar 2026 | $1.1B |
| Dec 2025 | -$1.9B |
| Sep 2025 | $836.0M |
| Jun 2025 | $1.2B |
| Mar 2025 | $236.0M |
| Dec 2024 | -$682.0M |
| Sep 2024 | $1.7B |
| Jun 2024 | $1.1B |
At each fiscal year end
Single quarter
Debt to equity
0.75x
long-term 2026-03-31 plus current 2026-03-31; equity 2026-03-31
Debt to equity HUM
| FY Dec 2025 | 0.70x |
| FY Dec 2024 | 0.72x |
| FY Dec 2023 | 0.72x |
| FY Dec 2022 | 0.73x |
| FY Dec 2021 | 0.78x |
| Mar 2026 | 0.75x |
| Dec 2025 | 0.70x |
| Sep 2025 | 0.68x |
| Jun 2025 | 0.69x |
| Mar 2025 | 0.75x |
| Dec 2024 | 0.72x |
| Sep 2024 | 0.74x |
| Jun 2024 | 0.77x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.13x
TTM operating cash flow over long-term 2026-03-31 plus current 2026-03-31
Cash flow to debt HUM
| FY Dec 2025 | 0.07x |
| FY Dec 2024 | 0.25x |
| FY Dec 2023 | 0.34x |
| FY Dec 2022 | 0.41x |
| FY Dec 2021 | 0.18x |
| Mar 2026 | 0.13x |
| Dec 2025 | 0.07x |
| Sep 2025 | 0.16x |
| Jun 2025 | 0.23x |
| Mar 2025 | 0.22x |
| Dec 2024 | 0.25x |
| Sep 2024 | -0.28x |
| Jun 2024 | -0.33x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+6.2%
TTM net income over average of 2025-03-31 and 2026-03-31
Return on equity HUM
| FY Dec 2025 | +7.0% |
| FY Dec 2024 | +7.4% |
| FY Dec 2023 | +15.8% |
| FY Dec 2022 | +17.9% |
| FY Dec 2021 | +19.7% |
| Mar 2026 | +6.2% |
| Dec 2025 | +7.0% |
| Sep 2025 | +7.2% |
| Jun 2025 | +9.0% |
| Mar 2025 | +10.1% |
| Dec 2024 | +7.4% |
| Sep 2024 | +7.9% |
| Jun 2024 | +10.2% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+2.1%
TTM net income over average of 2025-03-31 and 2026-03-31
Return on assets HUM
| FY Dec 2025 | +2.5% |
| FY Dec 2024 | +2.6% |
| FY Dec 2023 | +5.5% |
| FY Dec 2022 | +6.4% |
| FY Dec 2021 | +7.4% |
| Mar 2026 | +2.1% |
| Dec 2025 | +2.5% |
| Sep 2025 | +2.6% |
| Jun 2025 | +3.1% |
| Mar 2025 | +3.4% |
| Dec 2024 | +2.6% |
| Sep 2024 | +2.6% |
| Jun 2024 | +3.2% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+7.3%
operating income after a 17.8% effective tax rate, over long-term 2026-03-31 plus current 2026-03-31 plus average of 2025-03-31 and 2026-03-31 minus cash
Return on invested capital HUM
| FY Dec 2025 | +8.5% |
| FY Dec 2024 | +7.8% |
| FY Dec 2023 | +13.3% |
| FY Dec 2022 | +13.2% |
| FY Dec 2021 | +11.6% |
| Mar 2026 | +7.3% |
| Dec 2025 | +8.5% |
| Sep 2025 | +9.7% |
| Jun 2025 | +9.9% |
| Mar 2025 | +10.0% |
| Dec 2024 | +7.8% |
| Sep 2024 | +9.7% |
| Jun 2024 | +12.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+7.3%
operating income (EBIT proxy) over average of 2025-03-31 and 2026-03-31 minus current liabilities
Return on capital employed HUM
| FY Dec 2025 | +8.7% |
| FY Dec 2024 | +8.9% |
| FY Dec 2023 | +14.8% |
| FY Dec 2022 | +13.8% |
| FY Dec 2021 | +12.4% |
| Mar 2026 | +7.3% |
| Dec 2025 | +8.7% |
| Sep 2025 | +9.2% |
| Jun 2025 | +10.4% |
| Mar 2025 | +10.6% |
| Dec 2024 | +8.9% |
| Sep 2024 | +9.3% |
| Jun 2024 | +11.1% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
44.53x
close 2026-10-26 over four quarters of diluted EPS, 2025-04-01 to 2026-03-31
P/E, trailing HUM
| FY Dec 2025 | 26.03x |
| FY Dec 2024 | 25.45x |
| FY Dec 2023 | 22.91x |
| FY Dec 2022 | 23.20x |
| FY Dec 2021 | 20.45x |
| Mar 2026 | 18.50x |
| Dec 2025 | 26.03x |
| Sep 2025 | 24.34x |
| Jun 2025 | 18.73x |
| Mar 2025 | 18.69x |
| Dec 2024 | 25.45x |
| Sep 2024 | 27.66x |
| Jun 2024 | 26.35x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$59.1B
market value at close 2026-10-26 on 2026-03-31 shares, plus long-term 2026-03-31 plus current 2026-03-31, minus cash 2026-03-31
Enterprise value HUM
| FY Dec 2025 | $39.0B |
| FY Dec 2024 | $40.0B |
| FY Dec 2023 | $63.3B |
| FY Dec 2022 | $70.9B |
| FY Dec 2021 | $68.7B |
| Mar 2026 | $29.9B |
| Dec 2025 | $39.0B |
| Sep 2025 | $38.5B |
| Jun 2025 | $38.0B |
| Mar 2025 | $41.0B |
| Dec 2024 | $40.0B |
| Sep 2024 | $46.0B |
| Jun 2024 | $52.4B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+2.5%
TTM free cash flow over market value at close 2026-10-26
FCF yield HUM
| FY Dec 2025 | +1.2% |
| FY Dec 2024 | +7.8% |
| FY Dec 2023 | +5.3% |
| FY Dec 2022 | +5.3% |
| FY Dec 2021 | +1.5% |
| Mar 2026 | +6.1% |
| Dec 2025 | +1.2% |
| Sep 2025 | +4.9% |
| Jun 2025 | +8.3% |
| Mar 2025 | +7.5% |
| Dec 2024 | +7.8% |
| Sep 2024 | -11.4% |
| Jun 2024 | -11.2% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing EPS growth -34%, PEG needs growth
PEG, trailing HUM
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
| Jun 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $129.7B | $117.8B | $106.4B | $92.9B |
| Operating income | $2.7B | $2.6B | $4.0B | $3.8B |
| Net income | $1.2B | $1.2B | $2.5B | $2.8B |
| EPS (diluted) | 9.84 | 9.98 | 20.00 | 22.08 |
| Operating cash flow | $921.0M | $3.0B | $4.0B | $4.6B |
| Cash | $4.2B | $2.2B | $4.7B | $5.1B |
| Long-term debt | $12.4B | $11.1B | $10.2B | $9.0B |
| Buybacks | $151.0M | $817.0M | $1.6B | $2.1B |
| Dividends paid | $430.0M | $431.0M | $431.0M | $98.0M |
SEC XBRL, fiscal years, as known on 2026-10-28
HUM Stock Sonar score 5/7 axes
Find similar shapesCompareHUM ranks highest on growth (81st percentile) and risk and compliance (73rd), and lowest on financial health (17th), among Insurance peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
HUM filings, in plain words
Have members of Congress traded HUM?
Yes. In the year to 2026-10-28, 1 House member disclosed buying HUM and 3 House members disclosed selling it; the latest on record is a sale by Julia Letlow dated 2026-02-10.
Read the full summary
In the year to 2026-10-28, 1 member of Congress disclosed buying HUM and 3 members disclosed selling it; the latest on record is a sale by Julia Letlow dated 2026-02-10. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
